Publicaciones en colaboración con investigadores/as de University of Toronto (2)

2013

  1. A phase iii, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder

    Urology, Vol. 82, Núm. 2, pp. 313-320

2008

  1. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms

    Current Medical Research and Opinion, Vol. 24, Núm. 12, pp. 3513-3521